Spots Global Cancer Trial Database for First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
Official Title: A Phase I, Open-label Dose Escalation Study With Safety Expansion of TAS266 Administered by IV Infusion to Patients With Advanced Solid Tumors
Study ID: NCT01529307
Conditions
Interventions
Study Description
Brief Summary: This study will assess safety, tolerability, maximum tolerated dose or recommended dose for expansion of TAS266 administered by IV infusion to patients with advanced solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
H. Lee Moffitt Cancer Center/University of South Florida Moffitt SC, Tampa, Florida, United States
South Texas Accelerated Research Therapeutics START, San Antonio, Texas, United States
University of Utah / Huntsman Cancer Institute Huntsman UT, Salt Lake City, Utah, United States
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
